Your browser doesn't support javascript.
loading
Application of G-CSF in high-leukocyte acute myeloid leukemia is a poor prognostic factor.
Weng, Ping; Yang, Shu; Xu, Shujuan; Zhang, Shuxia; Wu, Yong; Chen, Yuanzhong.
Afiliação
  • Weng P; Fujian Provincial Key Laboratory on Hematology, Fujian Institute of Hematology, Fujian Medical University Union Hospital, Fuzhou, People's Republic of China.
  • Yang S; Fujian Provincial Key Laboratory on Hematology, Fujian Institute of Hematology, Fujian Medical University Union Hospital, Fuzhou, People's Republic of China.
  • Xu S; Fujian Provincial Key Laboratory on Hematology, Fujian Institute of Hematology, Fujian Medical University Union Hospital, Fuzhou, People's Republic of China.
  • Zhang S; Fujian Provincial Key Laboratory on Hematology, Fujian Institute of Hematology, Fujian Medical University Union Hospital, Fuzhou, People's Republic of China.
  • Wu Y; Fujian Provincial Key Laboratory on Hematology, Fujian Institute of Hematology, Fujian Medical University Union Hospital, Fuzhou, People's Republic of China.
  • Chen Y; Fujian Provincial Key Laboratory on Hematology, Fujian Institute of Hematology, Fujian Medical University Union Hospital, Fuzhou, People's Republic of China.
Hematology ; 28(1): 2220521, 2023 Dec.
Article em En | MEDLINE | ID: mdl-37278609
ABSTRACT

OBJECTIVE:

To analyze the effect of granulocyte colony-stimulating factor (G-CSF) on outcomes in patients with acute myeloid leukemia (AML).

METHODS:

A total of 526 patients with AML in the Haematology Department were enrolled. They were divided into a G-CSF treatment group and a no G-CSF group according to whether G-CSF was administered in the induction chemotherapy period, with 355 cases in the G-CSF group and 171 cases in the no G-CSF group. Cox regression analysis and Kaplan-Meier curve analysis were used to analyze the effect of G-CSF on the first complete remission (CR1) phase and overall survival (OS). In addition, further analysis was performed based on an initial white blood cell count of 50 * 10^9/L.

RESULTS:

The application of G-CSF significantly shortened the CR1 phase and OS in patients with high leukocytes.

CONCLUSIONS:

G/GM-CSF should be used with caution in patients with AML, especially those with high leukocytes.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Protocolos de Quimioterapia Combinada Antineoplásica Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Protocolos de Quimioterapia Combinada Antineoplásica Idioma: En Ano de publicação: 2023 Tipo de documento: Article